Novo Nordisk Inc v. Mylan Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: Mylan Pharmaceuticals Inc. (West Virginia)
  • Plaintiff's Counsel: Schrader Companion Duff & Law, PLLC
• Case Identification: 1:24-cv-00067, N.D. W. Va., 07/02/2024
• Venue Allegations: Venue is alleged to be proper as Defendant is a West Virginia corporation with its principal place of business in the district.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the diabetes drug Ozempic® constitutes an act of infringement of two patents covering the active pharmaceutical ingredient, semaglutide, and its method of use.
• Technical Context: The patents relate to long-acting glucagon-like peptide-1 (GLP-1) receptor agonists, a highly successful class of therapeutics for type 2 diabetes that reduces the need for frequent patient injections.
• Key Procedural History: This is a Hatch-Waxman action filed under 35 U.S.C. § 271(e)(2). The suit was triggered by a "Notice Letter" dated May 22, 2024, in which Mylan provided a Paragraph IV Certification stating that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by its proposed generic product. The complaint was filed within the 45-day statutory window following receipt of that notice.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,129,343 - "Acylated GLP-1 Compounds," issued March 6, 2012

The Invention Explained

• Problem Addressed: The patent's background section notes that many diabetes patients are subject to "needle-phobia," and the need for frequent injections of therapeutic peptides like GLP-1 can be a significant obstacle to patient compliance and effective treatment ʼ343 Patent, col. 2:41-53
• The Patented Solution: The invention is a chemically modified GLP-1 analog, semaglutide, designed for a longer duration of action ʼ343 Patent, col. 2:54-64 The solution involves two key modifications to the peptide backbone: an amino acid substitution at position 8 to protect against enzymatic degradation, and the attachment of a fatty acid-based side chain (acylation) to the lysine residue at position 26 ʼ343 Patent, col. 27:28-30 ʼ343 Patent, col. 58:17-34 This side chain enables the molecule to reversibly bind to albumin in the bloodstream, creating a circulating reservoir that extends the drug's half-life and allows for less frequent dosing ʼ343 Patent, col. 4:1-5
• Technical Importance: This acylation strategy provided a platform for creating long-acting peptide therapeutics, significantly reducing the treatment burden for patients with chronic diseases like type 2 diabetes.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-6 Compl. ¶19 Independent claims 1 and 4 are directed to the semaglutide compound itself, while independent claims 3 and 6 are directed to methods of using it to treat type 2 diabetes.
• Independent Claim 1:
  • A compound of the structure [depicting the chemical structure of semaglutide].
  • Where the amino acid sequence is that of SEQ ID NO: 7.
• Independent Claim 3:
  • A method for treating type 2 diabetes in a subject.
  • Comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a compound of the structure [depicting the chemical structure of semaglutide].
  • Where the amino acid sequence is that of SEQ ID NO: 7, and a pharmaceutically acceptable excipient.
• The complaint does not explicitly reserve the right to assert dependent claims, but the assertion of claims 1-6 encompasses the dependent claims within that range.

U.S. Patent No. 10,335,462 - "Use of Long-Acting GLP-1 Peptides," issued July 2, 2019

The Invention Explained

• Problem Addressed: The patent sought to define improved therapeutic uses and specific dosage regimens for long-acting GLP-1 agonists to maximize their clinical benefit ʼ462 Patent, col. 1:17-18
• The Patented Solution: The invention claims a specific method of treating type 2 diabetes by administering semaglutide at a dose of 1.0 mg once per week ʼ462 Patent, claim 1 The patent's specification provides clinical trial data suggesting that this particular regimen results in a surprisingly effective reduction in both HbA1c (a marker of blood sugar control) and body weight compared to other treatments ʼ462 Patent, col. 2:51-62 ʼ462 Patent, Fig. 1
• Technical Importance: The invention moved beyond the chemical composition to claim a specific, clinically validated dosage and schedule that demonstrated superior efficacy, thereby defining a new standard of care for this class of drug.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-10 Compl. ¶26
• Independent Claim 1:
  • A method for treating type 2 diabetes.
  • Comprising administering semaglutide.
  • Once weekly.
  • In an amount of 1.0 mg.
  • To a subject in need thereof.

III. The Accused Instrumentality

Product Identification

Defendant's proposed generic version of semaglutide injection, referred to as "Mylan's Product" Compl. ¶14

Functionality and Market Context

The complaint alleges that Mylan has submitted an ANDA seeking FDA approval to market a generic version of Novo Nordisk's brand-name product, Ozempic® Compl. ¶1 Compl. ¶14 As a generic drug, Mylan's Product is alleged to contain the same active ingredient, semaglutide, and is intended for the same use as Ozempic® Compl. ¶14 The complaint states that Mylan's ANDA contains data intended to demonstrate the bioequivalence of its product to Ozempic® Compl. ¶15 Ozempic® is a widely prescribed medication for type 2 diabetes, making a generic version a significant commercial product.

IV. Analysis of Infringement Allegations

The complaint provides a concise statement of infringement typical for an initial ANDA filing, without including detailed claim charts or specific evidentiary mapping. The infringement theories are based on the nature of the ANDA submission itself. No probative visual evidence provided in complaint.

Claim Chart Summary

U.S. Patent No. 8,129,343 Infringement Allegations

U.S. Patent No. 10,335,462 Infringement Allegations

Identified Points of Contention

• Scope Questions: In ANDA litigation, the central dispute is often not whether the proposed generic product falls within the literal scope of the claims, but whether the asserted patent claims are valid and enforceable. The complaint notes that Mylan's Paragraph IV certification asserts invalidity and/or non-infringement Compl. ¶16
• Technical Questions: A key question for the court will be the validity of the asserted patents. For the ʼ343 patent, this may involve assessing whether the specific chemical structure of semaglutide was obvious in light of prior art GLP-1 analogs. For the ʼ462 patent, the analysis may focus on whether the claimed "1.0 mg once weekly" dosing regimen was an inventive discovery or an obvious result of routine dose-finding studies.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for analysis of specific claim terms that may be subject to construction disputes. The asserted claims of the ʼ343 patent are directed to a specific chemical structure, and the asserted claims of the ʼ462 patent recite dosage parameters ("once weekly," "1.0 mg") that appear facially unambiguous. Any disputes are more likely to arise from validity challenges rather than claim construction.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Mylan's commercial marketing, sale, and proposed product labeling will intentionally induce healthcare providers and patients to use its generic product in a manner that infringes the asserted method claims of the ʼ343 and ʼ462 patents Compl. ¶20 Compl. ¶27
• Willful Infringement: The complaint alleges that Mylan was aware of both the ʼ343 patent and the ʼ462 patent at the time it submitted its ANDA, forming a basis for pre-suit knowledge Compl. ¶23 Compl. ¶30

VII. Analyst's Conclusion: Key Questions for the Case

As is common in Hatch-Waxman litigation, the central conflict will likely revolve around the validity of Novo Nordisk's patents rather than direct factual disputes over infringement. The case will present two primary questions for the court:

• A core issue will be one of inventiveness: For the ʼ343 patent, was the specific combination of an amino acid substitution at position 8 and the particular acylated side chain at position 26 an obvious design choice for a person of ordinary skill in the art seeking to create a long-acting GLP-1 analog, or does it represent a non-obvious invention?
• A key evidentiary question will be one of obviousness in clinical development: For the ʼ462 patent, does the claimed "1.0 mg once weekly" dosage regimen represent a patentable method of use, or would this specific dose and schedule have been an obvious parameter to test in routine clinical trials with a reasonable expectation of success for a known long-acting compound like semaglutide?